 |
|
|
| |
EXPEDITION-I: Efficacy and Safety of Glecaprevir/Pibrentasvir for Treatment of Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection in Adults with Compensated Cirrhosis
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-21 Amsterdam Netherlands
Xavier Forns1, Samuel Lee2, Joaquin Valdes3, Sabela Lens1, Reem Ghalib4, Humberto Aguilar5, Franco Felizarta6, Tarek Hassanein7, Holger Hinrichsen8, Diego Rincon9, Rosa Morillas10, Stefan Zeuzem11, Yves Horsmans12, David Nelson13, Yao Yu3, Preethi Krishnan3, Chih-Wei Lin3, Federico Mensa3
1Liver Unit, Hospital Clinic, CIBEREHD, IDIBAPS, Barcelona, Spain; 2University of Calgary, Alberta, Canada; 3AbbVie Inc., North Chicago, IL, USA; 4Texas Digestive Disease Consultants, Arlington, Texas, USA; 5Louisiana Research Center, LLC, Shreveport, LA, USA; 6Private Practice, Bakersfield, California, USA; 7Southern California Liver Centers and Southern California Research Center, Coronado, USA; 8Gastroenterology-Hepatology Center Kiel, Kiel, Germany; 9Liver Unit, Hospital General Universitario Gregorio Marañón, CIBERehd, Madrid, Spain; 10Liver Section and CIBERehd, Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 12J.W. Goethe University, Frankfurt, Germany; 13Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; 14Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA
|
| |
|
|
|
|
|
